News | EP Lab | May 14, 2019

Airport Security Body Scanners Do Not Interfere With Pacemakers, ICDs

Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions

Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.


May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such as pacemakers or implantable cardioverter defibrillators (ICDs), can safely travel through airport security checkpoint scanners. This is the first study to look at the relationship between body scanners and the impact on functionality of devices. The results were presented at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions and show no negative interference after analyzing more than 1,000 scans.

More than 3 million people across the world have pacemakers, a common CIED, as treatment for abnormal heart rhythms.[1] Body scanners are increasingly being used worldwide and are replacing conventional metal detectors. These scanners represent a potential new source of electromagnetic interference (EMI). EMI is a disturbance known to cause pacing inhibition or inappropriate shock therapy. Patients are advised to manage this potential risk by limiting their exposure to certain technologies including metal detectors, magnets, MRI scans and other medical procedures.

Prior to conducting the study, the authors surveyed more than 1,000 patients and found that 80 percent have fears or concerns about passing through body scanners at the airport. The survey information further reinforces the need to clarify the safety of airport security body scans for passengers with CIEDs.

The study included 375 patients enrolled between May 2017 and October 2018. The devices studied included implantable cardioverter defibrillators (ICD) (n=175, 47 percent), conventional pacemakers (PM) (n=127, 33 percent), subcutaneous ICD (S-ICD) (n=52, 14 percent), and leadless pacemakers (LCP) (n=21, 6 percent). The sensitivity levels of the devices were not altered, ICD shock therapy was disabled and permanent ventricular pacing were ensured to facilitate the detection of EMI. The primary endpoint was EMI events including pacing inhibition, upper rate tracking, tachycardia detection and spontaneous reprogramming. The secondary endpoint was the incidence of CIED detection by the body scanner.

Results from more than 1,000 body scans reported no interference with patient devices. There were no events of EMI during the body scans across 375 devices. Further, no CIEDs were detected by the body scanners (EMI-prevalence 0 percent [95 percent CI; 0 percent 1 percent]).

"We were surprised to learn that so many patients expressed concerns about the functionality of their devices while travelling. We wanted to help put their minds at ease by testing the potential interference body scanners could have on common devices like pacemakers and defibrillators," said lead author, Carsten Lennerz, M.D., MSci, German Heart Centre Munich. "Our study results show that now patients can travel worry-free knowing they can safely go through security checkpoints without the need of disclosing personal medical information."

The authors place importance on studies with larger patient populations and different types of body scanners. In addition, the studied the possible interference between devices and electric cars. "Do Electric Cars Impact Pacemakers and Defibrillators?" is also being presented at the meeting.

Read the related article "Driving a Tesla Car Does Not Cause Defibrillator Shocks."

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

Reference:
1. Wood, M. A., & Ellenbogen, K. A. (2002). Cardiac Pacemakers From the Patient’s Perspective. Circulation, 105(18), 2136-2138. doi:10.1161/01.cir.0000016183.07898.90


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now